AU2013231851A1 - Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use - Google Patents

Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use Download PDF

Info

Publication number
AU2013231851A1
AU2013231851A1 AU2013231851A AU2013231851A AU2013231851A1 AU 2013231851 A1 AU2013231851 A1 AU 2013231851A1 AU 2013231851 A AU2013231851 A AU 2013231851A AU 2013231851 A AU2013231851 A AU 2013231851A AU 2013231851 A1 AU2013231851 A1 AU 2013231851A1
Authority
AU
Australia
Prior art keywords
domain
polypeptide
protein
complex
surf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013231851A
Other languages
English (en)
Inventor
Ann DEWITT
John Edwards
Alex Franzusoff
Erik M. Vogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PERMEON BIOLOGICS Inc
Original Assignee
Permeon Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permeon Biologics Inc filed Critical Permeon Biologics Inc
Publication of AU2013231851A1 publication Critical patent/AU2013231851A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013231851A 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use Abandoned AU2013231851A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611493P 2012-03-15 2012-03-15
US61/611,493 2012-03-15
PCT/US2013/032686 WO2013138795A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Publications (1)

Publication Number Publication Date
AU2013231851A1 true AU2013231851A1 (en) 2014-09-11

Family

ID=49161881

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013231851A Abandoned AU2013231851A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Country Status (6)

Country Link
US (1) US20150266939A1 (https=)
EP (1) EP2825561A4 (https=)
JP (1) JP2015512246A (https=)
AU (1) AU2013231851A1 (https=)
CA (1) CA2867188A1 (https=)
WO (1) WO2013138795A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX
EP3610884B1 (en) * 2013-11-06 2021-08-18 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
BR112016013516A8 (pt) * 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
WO2015109012A1 (en) * 2014-01-14 2015-07-23 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
WO2016172187A1 (en) * 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to kras inhibitors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017120213A1 (en) * 2016-01-05 2017-07-13 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
CN105837665B (zh) * 2016-05-16 2019-04-30 江苏大学 特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110139870B (zh) * 2016-12-16 2023-12-01 爱维斯健有限公司 细胞膜穿透肽及包含其的细胞内输送载体
WO2018111051A1 (ko) * 2016-12-16 2018-06-21 (주)에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR101933217B1 (ko) * 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
US12150973B2 (en) 2018-05-03 2024-11-26 University Of Utah Research Foundation OCA-B peptide conjugates and methods of treatment
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
EP3808840A4 (en) * 2018-06-14 2022-03-23 Avixgen Inc. Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
JP7113918B2 (ja) * 2018-06-14 2022-08-05 アヴィックスジェン・インコーポレイテッド 細胞透過ペプチドと結合した融合タンパク質、および融合タンパク質または細胞透過ペプチドと上皮細胞成長因子を有効成分として含む組成物
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
KR102611974B1 (ko) * 2020-02-06 2023-12-11 아주대학교산학협력단 항원 유래 t 세포 항원 에피토프 또는 이를 포함하는 펩타이드를 세포 표면에 제시하기 위한 융합항체, 및 이를 포함하는 조성물
US20240401032A1 (en) * 2020-05-04 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
CN116194132A (zh) * 2020-07-13 2023-05-30 新加坡国立大学 肽佐剂对于其在病毒和肿瘤疫苗开发以及癌症免疫疗法和自身免疫性疾病诊断和治疗中的治疗应用
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用
EP4711380A1 (en) * 2024-09-16 2026-03-18 Fundació Institut Hospital del Mar d'Investigacions Mèdiques Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) * 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
WO2010119249A1 (en) * 2009-04-14 2010-10-21 Trojan Technologies Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
EP2424877A4 (en) * 2009-04-28 2013-01-02 Harvard College SUPRAGELADENE PROTEINS FOR CELL PENETRATION
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX

Also Published As

Publication number Publication date
WO2013138795A1 (en) 2013-09-19
US20150266939A1 (en) 2015-09-24
EP2825561A1 (en) 2015-01-21
EP2825561A4 (en) 2016-03-09
CA2867188A1 (en) 2013-09-19
JP2015512246A (ja) 2015-04-27

Similar Documents

Publication Publication Date Title
US20150266939A1 (en) Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
AU2005216126B2 (en) Binding peptidomimetics and uses of the same
KR20150023957A (ko) 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
CN106459187A (zh) 用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法
JP2021533203A (ja) Ｃｄ１３７とｐｄ−ｌ１に特異的な新規融合タンパク質
US20140271640A1 (en) FGF-10 Complexes
CN115461358A (zh) 一种细胞穿膜肽及其应用
US20150307576A1 (en) Fgf-10 complexes
JP2023509157A (ja) 細胞膜透過性ペプチドを含むループ状タンパク質
CN113614103A (zh) 不直接向其附着的细胞传导信号的非天然nkg2d受体
CN101633699B (zh) 一种含抗体模拟物的新型抗生素及其制备方法与应用
CN113227127A (zh) 向胃肠系统递送酬载的btnl3/8导引构建体
KR101790669B1 (ko) 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
US20240190934A1 (en) Engineered interleukin-10 and fusion proteins thereof
CN116829584A (zh) 一种抗pd-1的单域抗体
CN114716516B (zh) 鸡dec-205特异性结合的噬菌体展示多肽vs及其用途
WO2024003555A1 (en) Chemokine-binding peptides
EP3613766B1 (en) Polypeptide improved in protein purity and affinity for antigen, conjugate thereof with antibody or antigen-binding fragment, and preparation method therefor
WO2004046187A2 (en) Antibodies for in vitro use
CN119613545B (zh) 非天然氨基酸修饰的抗ccl5纳米抗体
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
CN113474357A (zh) 具有毒素和支架蛋白的融合蛋白
KR20130103299A (ko) Ｒｔｋ에 특이적으로 결합하는 ｒｔｋ―ｂｐｂ
HK40061399A (en) Non-natural nkg2d receptors that do not directly signal the cells to which they are attached

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period